Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$12.82
0.080.63%
At close: -
$12.82
0.000.00%
After Hours: 4:31 PM EDT
Comments
Loading...
Sotera Health Analyst Ratings and Price Targets | NASDAQ:SHC | Benzinga
Sotera Health Co has a consensus price target of $16.14 based on the ratings of 12 analysts. The high is $25 issued by Wolfe Research on January 11, 2023. The low is $8 issued by Goldman Sachs on November 23, 2022. The 3 most-recent analyst ratings were released by Goldman Sachs, Piper Sandler, and Barclays on May 5, 2025, April 23, 2025, and April 10, 2025, respectively. With an average price target of $14 between Goldman Sachs, Piper Sandler, and Barclays, there's an implied 9.20% upside for Sotera Health Co from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Goldman Sachs
Piper Sandler
Barclays
RBC Capital
Citigroup
1calculated from analyst ratings
Analyst Ratings for Sotera Health
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/05/2025 | Buy Now | 32.61% | Goldman Sachs | Matthew Sykes62% | $14 → $17 | Upgrade | Neutral → Buy | Get Alert |
| 04/23/2025 | Buy Now | 1.4% | Piper Sandler | Jason Bednar53% | $15 → $13 | Maintains | Neutral | Get Alert |
| 04/10/2025 | Buy Now | -6.4% | Barclays | Luke Sergott50% | $16 → $12 | Maintains | Overweight | Get Alert |
| 02/28/2025 | Buy Now | 24.8% | Barclays | Luke Sergott50% | $17 → $16 | Maintains | Overweight | Get Alert |
| 02/18/2025 | Buy Now | 32.61% | Barclays | Luke Sergott50% | $18 → $17 | Maintains | Overweight | Get Alert |
| 11/21/2024 | Buy Now | 32.61% | RBC Capital | Sean Dodge47% | $17 → $17 | Reiterates | Outperform → Outperform | Get Alert |
| 11/06/2024 | Buy Now | 56.01% | Citigroup | Patrick Donnelly80% | $18 → $20 | Maintains | Buy | Get Alert |
| 08/06/2024 | Buy Now | 32.61% | Barclays | Luke Sergott50% | $14 → $17 | Maintains | Overweight | Get Alert |
| 08/06/2024 | Buy Now | 32.61% | RBC Capital | Sean Dodge47% | $17 → $17 | Reiterates | Outperform → Outperform | Get Alert |
| 05/21/2024 | Buy Now | 1.4% | Piper Sandler | Jason Bednar53% | → $13 | Initiates | → Neutral | Get Alert |
| 04/10/2024 | Buy Now | 9.2% | Barclays | Luke Sergott50% | $19 → $14 | Maintains | Overweight | Get Alert |
| 04/03/2024 | Buy Now | 24.8% | Citigroup | Patrick Donnelly80% | $18 → $16 | Upgrade | Neutral → Buy | Get Alert |
| 03/25/2024 | Buy Now | 20.9% | Jefferies | David Windley73% | $15 → $15.5 | Upgrade | Hold → Buy | Get Alert |
| 03/11/2024 | Buy Now | 56.01% | RBC Capital | Sean Dodge47% | $20 → $20 | Reiterates | Outperform → Outperform | Get Alert |
| 03/04/2024 | Buy Now | 56.01% | RBC Capital | Sean Dodge47% | $20 → $20 | Reiterates | Outperform → Outperform | Get Alert |
| 02/28/2024 | Buy Now | 48.21% | Barclays | Luke Sergott50% | $17 → $19 | Maintains | Overweight | Get Alert |
| 02/06/2024 | Buy Now | — | Keybanc | Brett Fishbin54% | — | Initiates | → Sector Weight | Get Alert |
| 01/25/2024 | Buy Now | 32.61% | Barclays | Luke Sergott50% | $15 → $17 | Maintains | Overweight | Get Alert |
| 11/02/2023 | Buy Now | 56.01% | RBC Capital | Sean Dodge47% | $22 → $20 | Maintains | Outperform | Get Alert |
| 11/02/2023 | Buy Now | 17% | Barclays | Luke Sergott50% | $20 → $15 | Maintains | Overweight | Get Alert |
| 08/04/2023 | Buy Now | 71.61% | RBC Capital | Sean Dodge47% | $18 → $22 | Maintains | Outperform | Get Alert |
| 08/04/2023 | Buy Now | 79.41% | Keybanc | Matthew Mishan52% | $24 → $23 | Maintains | Overweight | Get Alert |
| 06/26/2023 | Buy Now | 87.21% | Keybanc | Matthew Mishan52% | → $24 | Upgrade | Sector Weight → Overweight | Get Alert |
| 06/22/2023 | Buy Now | — | Keybanc | Matthew Mishan52% | — | Maintains | Sector Weight | Get Alert |
| 05/04/2023 | Buy Now | 40.41% | RBC Capital | Sean Dodge47% | $19 → $18 | Maintains | Outperform | Get Alert |
| 05/04/2023 | Buy Now | 56.01% | Barclays | Luke Sergott50% | $21 → $20 | Maintains | Overweight | Get Alert |
| 04/04/2023 | Buy Now | 63.81% | Barclays | Luke Sergott50% | $22 → $21 | Maintains | Overweight | Get Alert |
| 03/01/2023 | Buy Now | 48.21% | RBC Capital | Sean Dodge47% | $8 → $19 | Maintains | Outperform | Get Alert |
| 01/23/2023 | Buy Now | 40.41% | JP Morgan | Casey Woodring27% | $6 → $18 | Upgrade | Underweight → Neutral | Get Alert |
| 01/11/2023 | Buy Now | 71.61% | Barclays | Luke Sergott50% | $6 → $22 | Upgrade | Underweight → Overweight | Get Alert |
| 01/11/2023 | Buy Now | 95.01% | Wolfe Research | Mike Polark57% | → $25 | Upgrade | Peer Perform → Outperform | Get Alert |
| 11/23/2022 | Buy Now | -37.6% | Goldman Sachs | Amit Hazan56% | $9 → $8 | Maintains | Neutral | Get Alert |
| 11/16/2022 | Buy Now | -53.2% | Barclays | Luke Sergott50% | $7 → $6 | Downgrade | Equal-Weight → Underweight | Get Alert |
| 11/15/2022 | Buy Now | -53.2% | Barclays | Luke Sergott50% | $7 → $6 | Downgrade | Equal-Weight → Underweight | Get Alert |
| 11/03/2022 | Buy Now | -53.2% | JP Morgan | Casey Woodring27% | $9 → $6 | Maintains | Underweight | Get Alert |
| 11/03/2022 | Buy Now | -37.6% | RBC Capital | Sean Dodge47% | $25 → $8 | Maintains | Outperform | Get Alert |
| 10/06/2022 | Buy Now | -37.6% | Barclays | Luke Sergott50% | $22 → $8 | Maintains | Equal-Weight | Get Alert |
| 10/05/2022 | Buy Now | -29.8% | Citigroup | Patrick Donnelly80% | → $9 | Downgrade | Buy → Neutral | Get Alert |
| 09/26/2022 | Buy Now | — | Keybanc | Matthew Mishan52% | — | Downgrade | Overweight → Sector Weight | Get Alert |
| 09/21/2022 | Buy Now | -29.8% | JP Morgan | Tycho Peterson83% | $26 → $9 | Downgrade | Overweight → Underweight | Get Alert |
| 09/20/2022 | Buy Now | -29.8% | Goldman Sachs | Amit Hazan56% | $23 → $9 | Downgrade | Buy → Neutral | Get Alert |
| 07/13/2022 | Buy Now | 71.61% | Barclays | Luke Sergott50% | $24 → $22 | Maintains | Equal-Weight | Get Alert |
| 06/09/2022 | Buy Now | 102.81% | Wolfe Research | Mike Polark57% | → $26 | Downgrade | Outperform → Peer Perform | Get Alert |
FAQ
What is the target price for Sotera Health (SHC) stock?
The latest price target for Sotera Health (NASDAQ:SHC) was reported by Goldman Sachs on May 5, 2025. The analyst firm set a price target for $17.00 expecting SHC to rise to within 12 months (a possible 32.61% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Sotera Health (SHC)?
The latest analyst rating for Sotera Health (NASDAQ:SHC) was provided by Goldman Sachs, and Sotera Health upgraded their buy rating.
When was the last upgrade for Sotera Health (SHC)?
The last upgrade for Sotera Health Co happened on May 5, 2025 when Goldman Sachs raised their price target to $17. Goldman Sachs previously had a neutral for Sotera Health Co.
When was the last downgrade for Sotera Health (SHC)?
The last downgrade for Sotera Health Co happened on November 16, 2022 when Barclays changed their price target from $7 to $6 for Sotera Health Co.
When is the next analyst rating going to be posted or updated for Sotera Health (SHC)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sotera Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sotera Health was filed on May 5, 2025 so you should expect the next rating to be made available sometime around May 5, 2026.
Is the Analyst Rating Sotera Health (SHC) correct?
While ratings are subjective and will change, the latest Sotera Health (SHC) rating was a upgraded with a price target of $14.00 to $17.00. The current price Sotera Health (SHC) is trading at is $12.82, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
